rituximab biosimilar (TL011) / Teva - LARVOL DELTA

TL011 in Severe, Active Rheumatoid Arthritis Patients (clinicaltrials.gov) - P1; N=54; Completed; Sponsor: Teva Pharmaceutical Industries, Ltd.; Phase classification: P1/2 ➔ P1

Clinical • Phase classification • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CD19 • CRP

TL011 in severe, active rheumatoid arthritis patients (clinicaltrials.gov) - P1/2, N=60; Recruiting -> Active not recruiting

Enrollment closed • Immunology • Rheumatoid Arthritis

Teva halts tests of cancer drug biosimilar (Haaretz) - Teva Pharmaceutical has suspended testing of generic version of rituximab at the third stage of clinical trials

Trial suspension • Biosimilar • Hematological Malignancies • Immunology • Rheumatoid Arthritis